Core Viewpoint - The company, Shenlian Biopharmaceutical (Shanghai) Co., Ltd., has signed a project contract with the Lanzhou Veterinary Research Institute to jointly develop multi-valent vaccines for swine and cattle, aiming to enhance disease prevention efficiency and reduce costs [1]. Group 1: Project Collaboration - The collaboration involves the development of multi-valent vaccines targeting three diseases for pigs and three for cattle, with both parties sharing the resulting technology and intellectual property [1]. - Each party will bear its respective costs as per the agreement, indicating a structured approach to resource allocation [1]. Group 2: Market Competitiveness - The anticipated vaccines are expected to achieve "one injection for four protections," which will reduce the number of immunizations required, thereby saving resources and costs while improving production efficiency [1]. - This initiative is projected to enhance the company's competitive edge in the animal health sector by providing comprehensive and efficient disease prevention solutions [1]. Group 3: Future Development Plans - The company plans to strengthen its collaboration with the Lanzhou Veterinary Research Institute, keeping pace with industry trends and accurately addressing changes in prevalent strains and clinical needs [1]. - Future efforts will focus on exploring the application potential of its R&D technology platform, accelerating breakthroughs in other multi-valent vaccines, mRNA vaccines, synthetic peptide vaccines, and virus-like particle (VLP) vaccines [1]. - The goal is to gradually form a clustered product matrix in disease prevention for pigs, ruminants, pets, and aquaculture, continuously enhancing the company's core competitiveness [1].

证券之星消息，7月31日动物保健板块较上一交易日下跌0.43%，大禹生物领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1611.97万元，游资资金净流出6281.9万元，散户 资金净流入7893.87万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300871 回盛生物 | | 6787.00万 | 7.85% | -4042.91万 | -4.68% | -2744.09万 | -3.17% | | 600201 | 生物股份 | 2619.98万 | 9.14% | -534.51万 | -1.86% | -2085.47万 | -7.28% | | 002868 *ST绿康 | | 940.97万 | 10.50% | -518.20 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-026 申联生物医药（上海）股份有限公司 关于与中国农业科学院兰州兽医研究所 签订多联多价疫苗项目合作开发合同的 自愿性披露公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，申联生物医药（上海）股份有限公司（以下简称"公司"）与中 国农业科学院兰州兽医研究所（以下简称"兰研所"）等单位签订了《猪口蹄疫 O 型/A 型、猪瘟、伪狂犬病三联疫苗技术开发（合作）合同》及《牛口蹄疫 O 型/A 型、病毒性腹泻/黏膜病、传染性鼻气管炎三联疫苗技术开发（合作）合同》， 共同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫病多联多 价疫苗，合作各方按照协议约定任务和分工，各自承担相关费用，合作研发项目 产生的技术成果及知识产权归公司及兰研所两方共同享有。 风险提示：本次合作研发属于新项目、新技术的研究开发。尽管在前期 的研究中已对两款产品进行了初步的安全性与有效性试验，但上述两款口蹄疫等 三种疫病多联多价疫苗产品最终能否通过农业农村部的行政审 ...

Core Viewpoint - The company, Shenlian Biological (688098.SH), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other entities to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties according to the agreements, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company, Shenlian Biological (688098), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to develop multi-valent vaccines for swine and cattle diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into a contract for the technical development of a tri-valent vaccine for swine, targeting foot-and-mouth disease (FMD) types O and A, swine fever, and pseudorabies [1] - Additionally, a contract has been signed for the development of a tri-valent vaccine for cattle, addressing FMD types O and A, viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

申联生物：与兰州兽医研究所签订多联多价疫苗项目合作开发合同 《科创板日报》31日讯，申联生物(688098.SH)公告称，公司与兰州兽医研究所等单位签订两份技术开 发（合作）合同，共同开发猪用和牛用口蹄疫等三种疫病多联多价疫苗。合作产生的技术成果及知识产 权归公司及兰研所两方共同享有。尽管两款产品已进行初步安全性与有效性试验，但能否通过农业农村 部审批及具体上市时间存在不确定性。 ...

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other entities to develop multi-valent vaccines for swine and cattle diseases, indicating a strategic move to enhance its vaccine portfolio and collaborative research efforts [1] Group 1 - The company is collaborating on the development of a tri-valent vaccine for swine diseases including Foot-and-Mouth Disease (FMD) type O/A, Classical Swine Fever (CSF), and Pseudorabies [1] - The company is also involved in the development of a tri-valent vaccine for cattle diseases including FMD type O/A, Viral Diarrhea/Mucosal Disease, and Infectious Bovine Rhinotracheitis [1] - The collaboration entails shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

证券之星消息，7月30日动物保健板块较上一交易日下跌0.46%，生物股份领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.98 | 7.65% | 7.08万 | 7555.51万 | | | 002868 | *ST绿康 | 26.73 | 4.99% | 2.78万 | 7294.48万 | | | 839729 | 永顺生物 | 10.02 | 1.83% | 4.19万 | 4168.45万 | | | 300871 | 回盛生物 | 22.22 | 1.37% | 16.18万 | | 3.63亿 | | 002688 | 金河生物 | 7.22 | 0.84% | 42.68万 | | 3.06亿 | | 688098 | 申联生物 | 6.90 | 0.73% | 10.01万 | 6919.84 ...

从资金流向上来看，当日动物保健板块主力资金净流出9984.08万元，游资资金净流出2164.17万元，散户 资金净流入1.21亿元。动物保健板块个股资金流向见下表： 证券之星消息，7月29日动物保健板块较上一交易日下跌0.5%，驱动力领跌。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 25.46 | 2.91% | 2.25万 | | 5731.13万 | | 688098 | 申联生物 | 6.85 | 1.33% | 10.41万 | | 7137.24万 | | 603566 | 普莱柯 | 15.23 | 0.40% | 5.03万 | | 7579.24万 | | 002688 | 金河生物 | 7.16 | 0.14% | 36.15万 | | 2.59亿 | | 688526 | 科前生物 | 17.2 ...